Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects

Journal of Clinical Pharmacology

Volumn 43, Issue 8, 2003, Pages 901-911

  Tarral, Antoine ^a   Dostert, Philippe ^a   Guillevic, Yann ^a   Fabbri, Laura ^b   Rondelli, Ivano ^b   Mariotti, Fabrizia ^b   Imbimbo, Bruno P ^b  

^a Biotrial SA   (France)

^b Research and Development Department   (Italy)

Author keywords

CHF 3381; Neuropathic pain; NMDA receptor antagonists; Pharmacodynamics; Pharmacokinetics

Indexed keywords

2 [(2,3 DIHYDRO 1H INDEN 2 YL)AMINO]ACETAMIDE; 2 AMINOINDAN; CHF 3381; CHF 3567; DRUG METABOLITE; N (2 INDAN 2 YL)GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ACCOMMODATION; ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; ATTENTION; BODY TEMPERATURE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; EYE DISEASE; FOOD DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALAISE; MALE; MAXIMUM TOLERATED DOSE; MEMORY; NAUSEA; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; URINARY EXCRETION; VERTIGO;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; FOOD; GLYCINE; HALF-LIFE; HUMANS; INDANS; MALE; MEMORY; METABOLIC CLEARANCE RATE; N-METHYLASPARTATE;

EID: 0037961047     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003256137     Document Type: Article

References (46)

1. Merskey H, Bogduk N: Classification of Cronich pain, in: IASP Taskforce on Taxonomy, 2nd ed. Seattle, WA: IASP Press, 1994;209-214.
2. Hansson P: Neuropathic pain: clinical characteristics and diagnostic workup. Eur J Pain 2002;6(Suppl. A):47-50.
3. Bennett GJ: Neuropathic pain: new insights, new interventions. Hosp Pract 1998;33:95-114.
4. Low PA, Dotson RM: Symptomatic treatment of painful neuropathy. JAMA 1998;280:1863-1864.
5. Cunningham AL, Dworkin RH: The management of post-herpetic neuralgia. Br Med J 2000;321:778-779.
6. Campbell JN: Nerve lesions and the generation of pain. Muscle Nerve 2001;24:1261-1273.
7. Attal N: Pharmacologic treatment of neuropathic pain. Acta Neurol Belg 2001;101:53-64.
8. Hempenstall K, Rice AS: Current treatment options in neuropathic pain. Curr Opin Investig Drugs 2002;3:441-448.
9. Collins SL, Moore RA, McQuay HJ, Wiffen P: Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage 2000;20:449-458.
10. Koltzenburg M, Scadding J: Neuropathic pain. Curr Opin Neurol 2001;14:641-647.
11. Hewitt DJ: The use of NMDA-receptor antagonists in the treatment of chronic pain. Clin J Pain 2000;16(2, Suppl.):S73-S79.
12. Sang CN: NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials. J Pain Symptom Manage 2000;19(Suppl.):S21-S25.
13. Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB: High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997;48:1212-1218.
14. Gilron I, Booher SL, Rowan MS, Smoller MS, Max MB: A randomized, controlled trial of high-dose dextromethorphan in facial neuralgias. Neurology 2000;55:964-971.
15. Eisenberg E, Kleiser A, Dortort A, Haim T, Yarnitsky D: The NMDA (N-methyl-D-aspartate) receptor antagonist memantine in the treatment of postherpetic neuralgia: a double-blind, placebo-controlled study. Eur J Pain 1998;2:321-327.
16. Nikolaisen L, Gottrup H, Kristensen AG, Jensen TS: Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. Anesth Analg 2000;91:960-966.
17. Villetti G, Bregola G, Bassani F, Bergamaschi M, Rondelli I, Pietra C, et al: Preclinical evaluation of CHF3381 as a novel antiepileptic agent. Neuropharmacology 2001;40:866-878.
18. Gandolfi O, Bonfante V, Voltattorni M, Dall'Olio R, Poli A, Pietra C, et al: Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms. Pharmacol Biochem Behav 2001;70:157-166.
19. Villetti G, Bergamaschi M, Bassani F, Bolzoni PT, Maiorino M, Pietra C, et al: Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist CHF3381 in experimental models of inflammatory and neuropathic pain. J Pharmacol Exp Ther; in press.
20. Zucchini S, Buzzi A, Bergamaschi M, Pietra C, Villetti G, Simonato M: Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate antagonist. Neuroreport 2002;13:2071-2074.
21. Jacobson BH, Edgley BM: Effects of caffeine on simple reaction time and movement time. Aviat Space Environ Med 1987;58:1153-1156.
22. Patat A: Clinical pharmacology of psychotropic drugs. Hum Psychopharmacol 2000;15:361-387.
23. Bond AJ, Lader MH: The use of analogue scales in rating subjective feeling. Br J Clin Psychol 1974;47:211-218.
24. Haertzen CA: Development of scales bases on patterns of drug effects, using the Addiction Research Center Inventory (ARCI). Psychol Rep 1966;18:163-194.
25. Allain H, Gandon JM: Psychopharmacology of memory components, in: Hindmarch I, Stonier P (eds.), Human Psychopharmacology: Measures and Methods. New York: John Wiley, 1993;143-164.
26. Warot D, Danjou P, Payan C, Puech AJ: Sensitivity and specificity to amphetamine of a French version of the 49-item form of the Addiction Research Center Inventory. Drug Alcohol Depend 1997;45:177-183.
27. Gottrup H, Bach FW, Arendt-Nielsen L, Jensen TS: Peripheral lidocaine but not ketamine inhibits capsaicin-induced hyperalgesia in humans. Br J Anaesth 2000;85:520-528.
28. Heiskanen T, Hartel B, Dahl ML, Seppala T, Kalso E: Analgesic effects of dextromethorphan and morphine in patients with chronic pain. Pain 2002;96:261-267.
29. Wilcock G, Mobius HJ, Stoffler A: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002;17:297-230.
30. Palmer GC, Clark B, Hutchison JB: Antiepileptic and neuroprotective potential of remacemide hydrochloride. Drugs Future 1993;18:1021-1042.
31. Muir KW, Grosset DG, Gamzu E, Lees KR: Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers. Br J Clin Pharmacol 1994;38:33-38.
32. Yenari MA, Bell TE, Kotake AN, Powell M, Steinberg GK: Dose escalation safety and tolerance study of the competitive NMDA antagonist selfotel (CGS 19755) in neurosurgery patients. Clin Neuropharmacol 1998;21:28-34.
33. Mueller AL, Artman LD, Balandrin MF, Brady E, Chien Y, Delmar EG, et al: NPS 1506, a novel NMDA receptor antagonist and neuroprotectant: review of preclinical and clinical studies. Ann N Y Acad Sci 1999;890:450-457.
34. Lees KR, Dyker AG, Sharma A, Ford GA, Ardron ME, Grosset DG: Tolerability of the low-affinity, use-dependent NMDA antagonist ARR15896AR in stroke patients: a dose-ranging study. Stroke 2001;32:466-472.
35. Walters MR, Bradford AP, Fischer J, Lees KR: Early clinical experience with the novel NMDA receptor antagonist CNS 5161. Br J Clin Pharmacol 2002;53:305-311.
36. Sagratella S: NMDA antagonists: antiepileptic-neuroprotective drugs with diversified neuropharmacological profiles. Pharmacol Res 1995;32:1-13.
37. Kochs E, Werner C, Hoffman WE, Mollenberg O, Schulte am Esch J: Concurrent increases in brain electrical activity and intracranial blood flow velocity during low-dose ketamine anaesthesia. Can J Anaesth 1991;38:826-830.
38. Oye I, Paulsen O, Maurset A: Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 1992;260:1209-1213.
39. van Berckel BN, Oranje B, van Ree JM, Verbaten MN, Kahn RS: The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects. Psychopharmacology 1998;137:271-281.
40. Oranje B, van Berckel BN, Kemner C, van Ree JM, Kahn RS, Verbaten MN: The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology 2000;22:293-302.
41. Mrongovius RI, Bolt AG, Hellyer RO: Comparison of the anorectic and motor activity effects of some aminoindanes, 2-aminotetralin and amphetamine in the rat. Clin Exp Pharmacol Physiol 1978;5:635-640.
42. Muir KW, Lees KR: Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995;26:503-513.
43. Stefansson T, Wickstrom I, Haljamae H: Hemodynamic and metabolic effects of ketamine anesthesia in the geriatric patient. Acta Anaesthesiol Scand 1982;26:371-377.
44. Grosset DG, Muir KW, Lees KR: Systemic and cerebral hemodynamic responses to the noncompetitive N-methyl-D-aspartate (NMDA) antagonist CNS1102. J Cardiovasc Pharmacol 1995;25:705-709.
45. Albers GW, Atkinson R, Kelley R, Rosenbaum DM: Safety, tolerability, and pharmacokinetics of the N-methyl D-aspartate antagonist dextrorphan in patients with an acute stroke. Neurology 1994;44(Suppl. 2):A270-A271.
46. Fisher K, Coderre TJ, Hagen NA: Targeting the N-methyl-D-aspartate receptor for chronic pain management: preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage 2000;20:358-373.